# Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

> **NCT00113815** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 118 (actual)

## Conditions studied

- Partial Seizure Disorder
- Epilepsy
- Seizures

## Interventions

- **DRUG:** topiramate
- **DRUG:** topiramate
- **DRUG:** topiramate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00113815
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-06
- **Final completion:** 2007-11
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113815, "Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00113815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*